$NANX
NANOPHASE TECHNOLOGIES Corp Stock $nanx

$nanx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000199937124005984 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$13.05M	$9.868M	$9.457M
YoY Change	9.89%	4.35%	15.95%
Cost Of Revenue	$9.306M	$6.287M	$7.308M
YoY Change	13.53%	-13.97%	22.04%
Gross Profit	$3.740M	$3.581M	$2.149M
YoY Change	1.77%	66.64%	-0.88%
Gross Profit Margin	28.67%	36.29%	22.72%
Selling, General & Admin	$1.829M	$1.551M	$2.150M
YoY Change	-13.11%	-27.86%	53.9%
% of Gross Profit	48.9%	43.31%	100.05%
Research & Development	$864.0K	$906.0K	$1.003M
YoY Change	-12.82%	-9.67%	50.6%
% of Gross Profit	23.1%	25.3%	46.67%
Depreciation & Amortization	$235.0K	$13.00K	$174.0K
YoY Change	36.63%	-92.53%	27.94%
% of Gross Profit	6.28%	0.36%	8.1%
Operating Expenses	$2.693M	$2.470M	$3.153M
YoY Change	-13.02%	-21.66%	52.84%
Operating Profit	$1.047M	$1.111M	-$1.004M
YoY Change	80.83%	-210.66%	-1056.19%
Interest Expense	$191.0K	-$218.0K	$155.0K
YoY Change	-22.36%	-240.65%	-460.47%
% of Operating Profit	18.24%	-19.62%
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income	$856.0K	$893.0K	-$1.159M
YoY Change	157.06%	-177.05%	-1969.35%
Income Tax		$0.00
% Of Pretax Income		0.0%
Net Earnings	$856.0K	$893.0K	-$1.159M
YoY Change	157.06%	-177.05%	-1969.35%
Net Earnings / Revenue	6.56%	9.05%	-12.26%
Basic Earnings Per Share	$0.02	$0.02	-$0.02
Diluted Earnings Per Share	$0.01	$0.01	-$0.02
COMMON SHARES
Basic Shares Outstanding	54.86M shares	54.80M shares	49.51M shares
Diluted Shares Outstanding	58.71M shares	58.04M shares	49.43M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.358M	$2.018M	$1.094M
YoY Change	7.33%	84.46%	21.96%
Cash & Equivalents	$2.358M	$2.018M	$1.094M
Short-Term Investments
Other Short-Term Assets	$2.096M	$1.550M	$933.0K
YoY Change	100.96%	66.13%	-7.16%
Inventory	$13.87M	$13.28M	$8.118M
Prepaid Expenses
Receivables	$5.932M	$5.227M	$4.380M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$24.26M	$22.08M	$14.53M
YoY Change	39.67%	51.99%	-7.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.261M	$16.43M	$8.235M
YoY Change	9.48%	99.45%	-50.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.000K	$3.000K	$4.000K
YoY Change	-60.0%	-25.0%	-42.86%
Total Long-Term Assets	$16.59M	$16.43M	$16.95M
YoY Change	-2.03%	-3.1%	1.38%
TOTAL ASSETS
Total Short-Term Assets	$24.26M	$22.08M	$14.53M
Total Long-Term Assets	$16.59M	$16.43M	$16.95M
Total Assets	$40.85M	$38.50M	$31.48M
YoY Change	19.09%	22.32%	-3.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.577M	$6.216M	$6.032M
YoY Change	12.51%	3.05%	21.78%
Accrued Expenses	$1.800M	$2.519M	$1.132M
YoY Change	24.83%	122.53%	-38.84%
Deferred Revenue
YoY Change
Short-Term Debt	$2.272M	$850.0K	$6.892M
YoY Change	-73.56%	-87.67%	85.82%
Long-Term Debt Due		$0.00	$1.000M
YoY Change		-100.0%	1328.57%
Total Short-Term Liabilities	$13.77M	$12.18M	$16.86M
YoY Change	-28.96%	-27.79%	47.52%
LONG-TERM LIABILITIES
Long-Term Debt	$6.200M	$6.200M
YoY Change
Other Long-Term Liabilities	$8.956M	$9.176M	$10.02M
YoY Change	-8.25%	-8.4%	-18.38%
Total Long-Term Liabilities	$15.16M	$15.38M	$10.02M
YoY Change	55.27%	53.48%	-24.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.77M	$12.18M	$16.86M
Total Long-Term Liabilities	$15.16M	$15.38M	$10.02M
Total Liabilities	$28.93M	$27.55M	$26.88M
YoY Change	-0.75%	2.5%	8.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$102.9M	-$103.8M	-$101.4M
YoY Change	1.8%	2.3%
Common Stock	$698.0K	$548.0K	$495.0K
YoY Change	40.73%	10.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.92M	$10.95M	$4.597M
YoY Change
Total Liabilities & Shareholders Equity	$40.85M	$38.50M	$31.48M
YoY Change	19.09%	22.32%	-3.02%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$856.0K	$893.0K	-$1.159M
YoY Change	157.06%	-177.05%	-1969.35%
Depreciation, Depletion And Amortization	$235.0K	$13.00K	$174.0K
YoY Change	36.63%	-92.53%	27.94%
Cash From Operating Activities	-$565.0K	-$3.855M	-$782.0K
YoY Change	-52.08%	392.97%	-55.94%
INVESTING ACTIVITIES
Capital Expenditures	$477.0K	$85.00K	$21.00K
YoY Change	-39.62%	304.76%	-105.56%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$477.0K	-$85.00K	-$21.00K
YoY Change	-39.62%	304.76%	-94.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.382M	$4.236M	-$289.0K
YoY Change	-55.01%	-1565.74%	-112.08%
NET CHANGE
Cash From Operating Activities	-565.0K	-$3.855M	-$782.0K
Cash From Investing Activities	-477.0K	-$85.00K	-$21.00K
Cash From Financing Activities	1.382M	$4.236M	-$289.0K
Net Change In Cash	340.0K	$296.0K	-$1.092M
YoY Change	-69.17%	-127.11%	-555.0%
FREE CASH FLOW
Cash From Operating Activities	-$565.0K	-$3.855M	-$782.0K
Capital Expenditures	$477.0K	$85.00K	$21.00K
Free Cash Flow	-$1.042M	-$3.940M	-$803.0K
YoY Change	-47.08%	390.66%	-42.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent		usd
CY2024Q1	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent		usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2023Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock		usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet		usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet		usd
CY2024Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet		usd
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock		shares
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	55000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	13281000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	10031000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1496000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1082000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	22077000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	16302000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8806000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8668000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7619000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7907000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4000	usd
CY2024Q1	us-gaap	Assets Assets	38504000	usd
CY2023Q4	us-gaap	Assets Assets	32881000	usd
CY2024Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	850000	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2810000	usd
CY2024Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	5200000	usd
CY2023Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	5000000	usd
CY2024Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	1000000	usd
CY2023Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	1000000	usd
CY2024Q1	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	240000	usd
CY2023Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	238000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15376000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15390000	usd
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	6000000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	24088	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	24088	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54860984	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54860984	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49627254	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49627254	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	548000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	496000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	108173000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	106069000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103770000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104663000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4951000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1902000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38504000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32881000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9868000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9457000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6288000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7308000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	3580000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	2149000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	910000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1003000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1559000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2150000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1111000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1004000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	155000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52675851	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49429407	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58035741	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49429407	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5649000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	101000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	209000	usd
CY2023Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	203000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1159000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4597000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1902000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1996000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	160000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	893000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	893000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4951000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4951000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	893000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1159000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	234000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	174000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	160000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	209000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1760000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-151000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3250000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-721000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	414000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	67000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-330000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-768000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	481000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	111000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2353000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	239000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-346000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	55000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-53000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	192000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3855000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-782000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	85000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-85000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21000	usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	200000	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1000000	usd
CY2024Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1960000	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1390000	usd
CY2024Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	2000000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	6000000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1996000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	101000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4236000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-289000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	296000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1092000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1722000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2186000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2018000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1094000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	160000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	97000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	286000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	437000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_zTIQ9Hv05Dyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(2) <span id="xdx_82A_zmo0784mSnja">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets.  Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the majority of our business and drive our forward growth strategy.  We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary.  In terms of our life sciences focus, we have seen demand decrease for our medical diagnostics ingredients. Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We target markets<span style="text-decoration: line-through">,</span> primarily related to skin health products and ingredients<span style="text-decoration: line-through">,</span> as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under SEC Release 33-10513; 34-83550, Amendments to Smaller Reporting Company Definition, the Company qualifies as a smaller reporting company and accordingly, it has scaled some of its disclosures of financial and non-financial information in this quarterly report. The Company will continue to determine whether to provide additional scaled disclosures of financial or non-financial information in future quarterly reports, annual reports and/or proxy statements if it remains a smaller reporting company under SEC rules. </span></p>
CY2022Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss ContractWithCustomerReceivableAfterAllowanceForCreditLoss	4734000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2188000	usd
CY2023Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss ContractWithCustomerReceivableAfterAllowanceForCreditLoss	3467000	usd
CY2024Q1	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss ContractWithCustomerReceivableAfterAllowanceForCreditLoss	5227000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2592000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	679000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1297000	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	55000	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	204000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	196000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	297636000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	128640000	usd
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	5359890	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	250000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	5109890	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1164000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	893000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1159000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52675851	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49429407	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	250000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	5109890	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58035741	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49429407	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	11354000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8524000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2690000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2184000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	763000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	677000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	13281000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	10031000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2024Q1	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	4320000	usd
CY2023Q1	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	2654000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9868000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9457000	usd

Files In Submission

Name	View Source	Status
0001999371-24-005984-index-headers.html	Edgar Link	pending
0001999371-24-005984-index.html	Edgar Link	pending
0001999371-24-005984.txt	Edgar Link	pending
0001999371-24-005984-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nanx-10q_033124.htm	Edgar Link	pending
nanx-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
nanx-10q_033124_htm.xml	Edgar Link	completed
nanx-20240331_cal.xml	Edgar Link	unprocessable
nanx-20240331_def.xml	Edgar Link	unprocessable
nanx-20240331_lab.xml	Edgar Link	unprocessable
nanx-20240331_pre.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NANX
NANOPHASE TECHNOLOGIES Corp Stock $nanx

2024 Q2 Form 10-Q Financial Statement

#000199937124005984 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NANX NANOPHASE TECHNOLOGIES Corp Stock $nanx

2024 Q2 Form 10-Q Financial Statement

#000199937124005984 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NANX
NANOPHASE TECHNOLOGIES Corp Stock $nanx